Osteoarthritic Pain – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of osteoarthritis (OA) pain comprises epidemiological estimates of key patient populations in the mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of OA pain for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s OA pain forecast will answer the following questions:
- Of all people with OA pain, how many in each country have been formally diagnosed?
- How many people diagnosed with OA pain are drug-treated?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following OA pain patient populations:
- Diagnosed prevalent cases.
- Diagnosed prevalent cases by drug-treatment status.
Table of contents
- Osteoarthritic Pain - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Overview
- Diagnosed Prevalence of Osteoarthritis Pain per 1,000 Adults in 2021 and 2041
- Diagnosed Prevalence of Osteoarthritis Pain per 1,000 Adults in 2021 and 2041
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Osteoarthritis Pain over the Next 20 Years
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Osteoarthritis Pain over the Next 20 Years
- Number of Additional Prevalent Cases of Diagnosed Osteoarthritis Pain in 2041 in the Countries Under Study due to Trends in Risk
- Number of Additional Diagnosed Prevalent Cases of Osteoarthritis Pain in 2041 in the Countries Under Study due to Trends in Risk
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Aishwarya S. Ambat, M.P.H., Epidemiologist , Epidemiology. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy. Her areas of interest are rheumatic disease and cancer epidemiology.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.